Clinical Trial Update: Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing deferiprone for oxidative stress and iron overload in low-risk transfusion-dependent myelodysplastic syndrome patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Deferiprone (deferiprone)

Snippet

Sponsor: Sheba Medical Center | Conditions: Myelodysplastic Syndrome With Low-grade Lesions, Iron Overload Due to Repeated Red Blood Cell Transfusions | Phase 2 | Status: COMPLETED